| HOME >> BIOLOGY >> TECHNOLOGY |
administrative 7,879 6,380 22,465 22,966
Acquired research and
development milestone - 7,500 - 7,500
Restructuring charges - 317 - 10,246
Total costs and
expenses 35,236 41,126 108,048 133,596
Loss from operations (11,913) (29,755) (67,297) (76,531)
Interest income 1,212 2,510 4,644 7,754
Interest expense (1,520) (726) (4,101) (2,185)
Other income (expense) 18 (196) 1,286 2,326
Loss from continuing
operations before income
taxes (12,203) (28,167) (65,468) (68,636)
Income tax expense 325 - - -
Loss from continuing
operations (12,528) (28,167) (65,468) (68,636)
Discontinued operations:
Income (loss) from
discontinued operations (3) 5,043 71 4,915
Net loss $(12,531) $(23,124) $(65,397) $(63,721)
Basic and diluted loss per
share:
Continuing operations $(0.32) $(0.81) $(1.68) $(1.99)
Discontinued operations - 0.15 - 0.14
Net loss per share $(0.32) $(0.66) $(1.68) $(1.85)
Shares used in computing
basic and diluted net loss
per share 39,031 34,801 38,954 34,394
InterMune, Inc.
PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands)
Sept 3
'/>"/>
| SOURCE InterMune, Inc. Copyright©2008 PR Newswire. All rights reserved |